Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

MSN Laboratories Pvt. Ltd. is appealing rulings that block the early launch of its copy of Entresto and preserve Novartis ...

Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal ...

Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor for ADPKD to its ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...